(Press-News.org) ORLANDO, Fla. — Scientists have uncovered a genetic characteristic of metastatic prostate cancer that defines a rare sub-type of this disease. These findings are published in Cancer Discovery, the newest journal of the American Association for Cancer Research, which will debut at the AACR 102nd Annual Meeting 2011, held April 2-6.
Arul M. Chinnaiyan, M.D., Ph.D., an investigator of the Howard Hughes Medical Institute and director of the Michigan Center for Translational Pathology, and colleagues identified an oncogenic gene fusion of KRAS, one of the most studied and well-known oncogenes in a metastatic prostate cancer cell line.
Like most metastatic disease, metastatic prostate cancer has a grim prognosis. As scientists learn more about the genetic characteristics of this disease, they may be able to work backward and accurately predict which early-stage prostate cancers will be more aggressive and thus require additional therapy and management.
"Right now, we can identify the presence of prostate cancer but not accurately predict which of these cancers will have a poor prognosis," said Chinnaiyan. "Although prostate cancer is a leading cause of cancer-related death, we need better prognostic information to separate the slow growing tumors from the more aggressive ones."
Chinnaiyan compared the identification of the KRAS gene in metastatic prostate cancer to the work that has been previously done in breast cancer, where scientists now recognize that breast cancer comes in multiple subtypes and requires different treatment strategies.
"The more we know about the disease biologically, the better we'll be able to treat it," said Chinnaiyan.
Currently, there are no treatments that block the KRAS oncogene, but several are under development that target components of the KRAS signaling pathway.
###
This abstract will be presented at an AACR press conference on Sunday, April 3 at 1:00 p.m. ET in room W313 of the Orange County Convention Center. Reporters who cannot attend in person can participate using the following information:
U.S. & Canada: (888) 647-7462
International: (201) 604-0169
Access Code: 244088
Press registration for the AACR 102nd Annual Meeting 2011 is free to qualified journalists and public information officers: http://www.aacr.org/PressRegistration
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.
Scientists identify KRAS rearrangements in metastatic prostate cancer
2011-04-03
ELSE PRESS RELEASES FROM THIS DATE:
New target identified for squamous cell lung cancer
2011-04-03
ORLANDO, Fla. — Scientists at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib.
The findings are published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, from April 2-6.
According to lead researcher Matthew Meyerson, M.D., Ph.D., professor of pathology at the Dana Farber Cancer Institute, there are currently no targeted therapies for squamous cell lung cancer, ...
Immune system may guide chemotherapy for breast cancer
2011-04-03
ORLANDO, Fla. — A study published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, held April 2-6, showed how evaluating the immune response in the tumor microenvironment may help researchers better target therapy in breast cancer.
Researchers at the University of California, San Francisco, demonstrated that the level of macrophages and CD8+ T-cells, two key components of the human immune system, can help predict recurrence and overall survival. New biologic-targeted therapies ...
Digoxin may be a possible treatment for prostate cancer
2011-04-03
ORLANDO, Fla. — Scientists have identified digoxin as a possible therapy for prostate cancer, using a combination of laboratory science and epidemiology that is unprecedented in its cooperative nature.
"Epidemiologists and basic scientists often do not understand each other, as we often are only clear on our own strengths and the other's weaknesses," said Elizabeth Platz, Sc.D., M.P.H, professor of epidemiology and the Martin D. Abeloff, M.D., scholar in cancer prevention at Johns Hopkins University.
For the current paper, published in Cancer Discovery, the newest ...
Large Veterans Health Administration study shows 'last resort' antibiotics use on the rise
2011-04-03
Dallas, TX (April 3, 2011) – A large, multi-year study of antibiotic use in Veterans Health Administration's acute care facilities demonstrates dramatically increased use of carbapenems, a powerful class of antibiotics, over the last five years. These drugs are often considered the last treatment option for severe infections with multi-drug resistant pathogens. The increased carbapenem use, which has also been described in non-VA facilities in the US, is alarming because carbapenem-resistant bacteria are becoming more common. Overuse of these drugs could weaken their efficacy, ...
Search for advanced materials aided by discovery of hidden symmetries in nature
2011-04-03
A new way of understanding the structure of proteins, polymers, minerals, and engineered materials will be published in the May 2011 issue of the journal Nature Materials. The discovery by two Penn State University researchers is a new type of symmetry in the structure of materials, which the researchers say greatly expands the possibilities for discovering or designing materials with desired properties. The research is expected to have broad relevance in many development efforts involving physical, chemical, biological, or engineering disciplines including, for example, ...
Heart drug cuts prostate cancer risk; holds potential for therapeutic use
2011-04-03
Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The scientists say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer.
Digoxin, made from the foxglove plant, has been used for centuries in folk medicine and for decades to treat congestive heart failure and heart rhythm abnormalities. It also emerged as a leading candidate among 3,000 drugs screened by the Johns ...
Nanoparticles offer hope for common skin allergy
2011-04-03
Boston, MA - Tiny particles only billionths of a meter in diameter—about two thousand would fit across the width of a human hair—could offer big hope in a small package to the many millions of people who are allergic to the nickel in everything from jewelry to coins and cell phones, say scientists at Brigham and Women's Hospital (BWH).
In the April 3 online issue of Nature Nanotechnology, the team will report a new approach to preventing the common skin allergy.
Approximately ten to fifteen percent of the US population, or over 30 to 45 million people, plus many more ...
BestSlots.co.uk Wins Endorsement From eCOGRA for Its Online Slots Guide
2011-04-03
Following a successful first year online delivering independent consumer news and reviews for UK online slots enthusiasts, BestSlots.co.uk has cemented its reputation for trustworthy content and service with recognition by eCOGRA (eCommerce and Online Gaming Regulation and Assurance) as one of its Reputable Portals.
The eCOGRA organisation is a non-profit, independent regulatory body that was formed with a mission to protect players by addressing the need for fair gaming and responsible operator conduct, setting standards for the online gaming industry that are enforced ...
Regional prevention project involving 10,000 adults cuts heart attacks by 25 percent
2011-04-03
The Heart of New Ulm Project, which is merging environmental, peer leadership and individual interventions across an entire rural Minnesota community with the assistance of a healthcare system, worksites and the general community to prevent coronary heart disease, has shown a 24 percent reduction in the number of acute heart attacks in a five-quarter period, compared with the previous five-quarter period of evaluation.
This study will be presented at the 60th annual American College of Cardiology (ACC) Scientific Sessions in New Orleans on April 3.
“Hearts Beat Back: ...
Videgameprices.co.uk Brings UK Gamers More Bang for Their Buck
2011-04-03
Videogameprices.co.uk is a new online resource for PC and console gamers dedicated to helping them track down the best current prices on popular titles. Taking its cue from the huge success of UK price comparison sites such as gocompare.com and comparethemarket.com in the realms of finance and insurance products, Videogameprices.co.uk has set out to provide UK gamers with a streamlined service tailored specifically to their interests, aggregating the latest comparative prices from the most competitive, reputable games retailers.
The company's founder, David Newstead, ...